Evolution Invented the Same Toxin Defense Repeatedly

Convergence at the Molecular Level

A new study published in Science has uncovered one of the most striking examples of convergent evolution ever documented at the molecular level. Researchers found that multiple unrelated animal species have independently evolved defensive toxins that mimic bradykinin, a peptide that plays a central role in the human pain and inflammation response. The convergence is so precise that these independently evolved toxins interact with the same human receptors through nearly identical molecular mechanisms, despite emerging from completely different evolutionary lineages.

Bradykinin is a naturally occurring peptide in mammals that dilates blood vessels, increases vascular permeability, and triggers pain signaling. It is released during tissue injury as part of the body's inflammatory response. The discovery that diverse venomous and toxic animals have independently stumbled upon molecular mimics of this specific peptide suggests that bradykinin represents a particularly effective molecular target for defensive weapons — so effective that evolution has converged on it again and again.

The Species Involved

The study analyzed toxins from a range of taxonomically distant species, including certain venomous snakes, frogs, insects, and marine organisms. In each case, the defensive secretions contained peptides that were structurally distinct from each other in their amino acid sequences but functionally equivalent in their ability to bind to and activate bradykinin receptors in mammalian tissue. This functional convergence despite structural divergence is the hallmark of independent evolutionary invention rather than shared ancestry.

The research team used advanced protein structure prediction tools to model the three-dimensional shapes of these toxin peptides and compare their receptor-binding surfaces. Despite having different evolutionary origins and different overall shapes, the toxins shared critical binding features at the molecular interface where they contact the bradykinin receptor. This convergence at the binding interface, rather than across the entire molecule, demonstrates that evolution found multiple structural solutions to the same functional problem.

Science

Researchers at The University of Osaka have developed a catalyst that uses vibrational energy to convert carbon dioxide into carbon monoxide, a key industrial feedstock.

DT Editorial AI·Apr 22, 2026·via phys.org

Science

MIT researchers report that a classical formulation based on the principle of least action can reproduce standard quantum results in scenarios such as tunneling and the double-slit experiment.

DT Editorial AI·Apr 22, 2026·via phys.org

Science

A newly developed mathematical tool could give researchers a more practical way to distinguish complex knots, a longstanding challenge in topology and related sciences.

DT Editorial AI·Apr 22, 2026·via quantamagazine.org

Science

A new research effort describes a dynamic framework for monitoring tillage practices from space, aimed at improving visibility into no-till and reduced-till adoption across the Midwest.

Implications for Drug Development

The discovery has practical implications beyond evolutionary biology. The bradykinin pathway is already a target for pharmaceutical research, particularly in the treatment of hereditary angioedema, a condition caused by overactive bradykinin signaling, and in the development of pain management therapies. The diverse collection of naturally evolved bradykinin mimics identified in the study represents a library of molecular structures that drug developers can investigate as potential therapeutic agents or as templates for designing synthetic bradykinin receptor modulators.

Each independently evolved mimic provides a different structural approach to activating the same receptor, and some of these structures may have pharmacological properties — such as selective receptor subtype binding, altered duration of action, or improved stability — that natural bradykinin lacks. The study effectively provides pharmaceutical researchers with a set of evolutionary experiments that have already been conducted over millions of years, each yielding a potentially useful molecular scaffold.